Meta-analysis of DC-CIK or CIK combined with chemotherapy in the treatment of advanced non-small cell lung cancer

Objective: To study the clinical efficacy of biological immune therapy of dendritic cell(DC) or cytokine-induced killers cell(CIK) combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC) by using Meta-analysis and systematic review of the literature.Methods: Randomized controlled trials(RCT) papers were searched in China Academic Journals,China National Knowledge Infrastructure,WeiPu and Wanfang database,PubMed and CBM foreign database.Jadad scale was used to devalue the quality of the included papers;Meta-analysis of the clinical efficacy,the life quality and the immunologic function(CD3⁺、CD4⁺、CD4⁺/CD8⁺) was performed with Revman 4.2 software.Results: Eleven RCT papers were included after screening,and the quality of the papers obtained low Jadad score.Meta-analysis showed that the odds ratio(OR) of the combined clinical benefit rate was 2.45,95% CI 1.56 to 3.83;the OR of the life quality was 3.17,95%CI 1.82 to 5.52.After treatment,the levels of CD3⁺ in the immunotherapy group increased to 16.96,95%CI 14.09 to 17.82,the levels of CD4⁺ increased to 6.84,95%CI 6.06 to 8.63 and the levels of CD4⁺/CD8⁺ increased to 0.60,95%CI 0.56 to 0.65.The clinical benefit rate and the immunologic function rate of the DC-CIK therapy or CIK combined with chemotherapy were superior to those of the control in the treatment of NSCLC.Conclusions: Biological immune therapy of DC-CIK or CIK combined with chemotherapy can help to improve the clinical benefit rate,the life quality and immunologic function of the patients with advanced NSCLC.